World of DTC Marketing https://validator.w3.org/feed/docs/rss2.html Pharma’s Oncology Targeting Model Is Missing Part of the Care Team Could Pharma Put an AI Query Box on Drug Websites—and Survive FDA Scrutiny? Pharma Websites Are Scaring Away the Very Patients They Want to Reach Why Most Pharma Companies Need External Consultants How Pharma Should Build a Social Media Intelligence System The New Patient Journey: How Online Health Seekers Are Making Treatment Decisions—and Why Drug Price Matters More Than Ever Stop Counting MSL Calls: The Best Ways to Evaluate Medical Affairs and MSLs The Worst-Led Big Pharma Companies of 2026 A Breakthrough in Pancreatic Cancer — But Will Patients Be Able to Afford It? Pharma Needs to Change—Because Healthcare Is Changing Faster Than Pharma A Quick Guide to Influencing Senior Executives as a Pharma Marketer The Real Economics of the New Pancreatic Cancer Drug: When Six More Months Could Cost Hundreds of Thousands No, You Can’t Hide Promotion Inside “Unbranded” Disease Education $39,800 a Month for a Cancer Pill: When Does the Price of Innovation Become Too High? Mounjaro.com Is More Than a Drug Website — It’s a Look at the Future of Pharma Marketing Finally, Some Evidence Employers Can Use to Justify Covering GLP-1s Great Pharma DTC Marketers Leave the Spreadsheet and Listen to Patients Pharma Sold America on Weight Loss. It Forgot to Tell Patients About Muscle. The Healthcare Squeeze Is Coming for the American Paycheck Pharma Is Wasting Millions Building Websites Nobody Wants to Navigate Pharma’s Experience Problem: When “Yes” Becomes More Valuable Than Judgment Employers Can Take Control of Healthcare Costs — They Just Have to Stop Playing Defense Anymore Prior Authorization Isn’t Just Controlling Costs. It’s Making Denials Too Costly To Fight. If Pharma Wants Employers to Cover GLP-1s, Prove They Lower Total Healthcare Costs How Many of Us Can Actually Afford Cancer Care? Pharma Has More Data Than Ever. So Why Are We Still Surprised by the Market? Information Asymmetry Is One of the Business Models Underlying American Healthcare How Much Has AbbVie Cost U.S. Healthcare by Gaming the Patent System? Pharma Is Falling in Love With AI Market Research. But Are We About to Stop Listening to Real Patients? Yale Single-Payer Health Study: Pros and Cons Heidi Overton Is the Wrong Choice for FDA Commissioner The Unsustainable Cost of Healthcare: A Voter’s Primary Concern No,Washington Won’t Ban Pharma TV Ads Should Employers Cover GLP-1 Drugs? The Answer Isn’t as Simple as Yes or No Why Is Pharma Still Making the Same Mistakes in Leadership and Hiring? Medical Affairs Is Losing Its Way—and Pharma’s Hiring Practices Are Making It Worse Zenbexus: Is BMS Bringing the Future of Multiple Myeloma—or Revlimid 2.0—to a Market That Has Already Moved On? PR Releases On Prior Authorizations Don’t Tell A Story You Can Do Everything Right in America—and Cancer Can Still Bankrupt You Does Pharma Care What GLP-1s Are Doing to Employer Healthcare Costs? Pharma’s $5 Billion Question: What Value Does a Sales Representative Actually Add? Americans Agree Health Care Is Broken.. The Pharma Website Nobody Wants to Visit Pharma Marketers Are Measuring the Campaign—and Missing the Patient For Pharma, LinkedIn Has Become A PR Bulletin Board What Physicians Really Think About Big Pharma AI Can Recommend the Treatment. But Who Owns the Decision? Are Prescription Drug Prices Really Falling? Not So Fast. We’re Paying For Universal Healthcare Already How Do We Recognize the Patient-Centered Marketers in Pharma?